Hesperidin: A Therapeutic Agent For Obesity.
Haijun XiongJin WangQian RanGuanhua LouChengyi PengQingxia GanJu HuJilin SunRenchuan YaoQin-Wan HuangPublished in: Drug design, development and therapy (2019)
Obesity is a chronic metabolic disease caused by multiple factors and is considered to be a risk factor for type 2 diabetes, cardiovascular disease, hypertension, stroke and various cancers. Hesperidin, a flavanone glycoside, is a natural phenolic compound with a wide range of biological effects. Mounting evidence has demonstrated that hesperidin possesses inhibitory effect against obesity diseases. Our review discusses mechanisms of hesperidin in the treatment of obesity. Hesperidin regulates lipid metabolism and glucose metabolism by mediating AMPK and PPAR signaling pathways, directly regulates antioxidant index and anti-apoptosis, and indirectly mediates NF-κB signaling pathway to regulate inflammation to play a role in the treatment of obesity. In addition, hesperidin-enriched dietary supplements can significantly improve symptoms such as postprandial hyperglycemia and hyperlipidemia. Further clinical trials are also required for confirming lipid-lowering efficacy of this natural flavonoid and evaluating its safety profile.
Keyphrases
- type diabetes
- insulin resistance
- signaling pathway
- metabolic syndrome
- high fat diet induced
- weight loss
- cardiovascular disease
- oxidative stress
- weight gain
- clinical trial
- high fat diet
- adipose tissue
- skeletal muscle
- glycemic control
- blood pressure
- epithelial mesenchymal transition
- immune response
- fatty acid
- randomized controlled trial
- physical activity
- cell death
- endoplasmic reticulum stress
- blood glucose
- toll like receptor
- subarachnoid hemorrhage
- drug induced
- protein kinase
- cell cycle arrest
- double blind
- open label